Results 1 to 10 of about 687 (60)

Фармакоэкономика туберкулезной инфекции у детей

Экспериментальная и клиническая фармакология, 2023
--
Надежда Юрьевна Усачева, Василий Егорович Новиков, Татьяна Владимировна Мякишева   +2 more
semanticscholar   +1 more source

Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years

Качественная клиническая практика, 2022
Relevance. Studies devoted to the assessment of consumption, as well as to the issues of pharmacosafety of nonsteroidal anti-inflammatory drugs, are limited at the national level in the Russian Federation.
G. I. Syraeva, A. S. Kolbin, S. A. Mishinova, A. A. Kalyapin   +3 more
doaj   +1 more source

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Качественная клиническая практика, 2021
Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base

Качественная клиническая практика, 2021
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Agonists of receptors for glucagon like peptide-1 (aGLP-1) are one of the modern option for glycemia control in DM Type 2 ...
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Farmakoekonomicheskie aspekty umen'sheniya mikroa11'buminurii u bol'nykh gipertonicheskoy bolezn'yu i sakharnym diabetom tipa 2

Сахарный диабет, 2004
У больных гипертонической болезнью и СД с МА наиболее оправданным с фармакоэкономических позиций является применение индапамида-ретард и эналаприла в дозе, не превышающей 12 мг/сут.
V Petrov, S Nedogoda, A Sabanov
doaj   +1 more source

Farmakoekonomicheskiy analiz ispol'zovaniya intensivnoy taktiki lecheniya bol'nykh sakharnym diabetom 2 tipa

Сахарный диабет, 2004
Цель. Оценка клинических показателей интенсивной инсулинотерапии и комбинированной терапии инсулином и пероральными сахароснижающим препаратами (ПССП) больных СД 2 для достижения целевых значений ...
Olga Mikhailovna Smirnova
doaj   +1 more source

PHARMACOECONOMICS OF APPLICATION OF HEPATOPROTECTORS IN THERAPY OF DRUG-INDUCED LIVER INJURY AFTER CHEMOTHERAPY

Acta Biomedica Scientifica, 2017
One of the major problems of modern oncology drug is liver damage, requiring additional costs for its treatment. The aim of our work was to study medical and economic efficiency of various schemes of hepatoprotective treatment of toxic liver damage.
D. D. Morikov, E. G. Morikova, D. M. Ponomarenko   +2 more
doaj   +1 more source

Pharmacoeconomic evaluation of the ceftolosan + tasobactam in the treatment of complicated nosocomial intraabdominal infections

Качественная клиническая практика, 2019
Objective. To perform the pharmacoeconomic analysis of ceftolosan + tazobactam (Zerbaxa®) compared with the routine practice of antibacterial therapy of complicated intra-abdominal infections (clAI) and ceftazidime + avibactam (Zavicefta®).Methods.
I. N. Dyakov, S. K. Zyryanov, N. N. Khachatryan   +2 more
doaj   +1 more source

Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues

Clinical oncohematology, 2019
Background & Aims. At least one third of patients with diffuse large B-cell lymphoma (DLBCL) are resistant to fi rst-line therapy. R-CHOP chemo-immunotherapy does not yield acceptable results in high-risk patients.
K. Kaplanov, N. Volkov, T. Klitochenko, I. Matveeva, A. Shipaeva, M. Shirokova, N. Davydova, E. Gemdzhian, D. Abramov, D. Konovalov, Gl Snigur, N. Red'kina, A. A. S. V. R. F. Diagnosis Polyclinic No., Samory Mashela str. Moscow Russian Federation Immunology   +13 more
semanticscholar   +1 more source

Hodgkin’s Lymphoma: Analysis Results of Volgograd Regional Registry

Clinical oncohematology, 2019
Background. The present paper discusses feasibility of fi rstand second-line therapies as well as the signifi cance of different risk factors in the population of all patients with newly diagnosed Hodgkin’s lymphomas (HL) in a 14-year period based on the
K. Kaplanov, N. Volkov, T. Klitochenko, I. Matveeva, A. Shipaeva, M. Shirokova, N. Davydova, E. Gemdzhian, A. A. S. V. R. F. Diagnosis Polyclinic No.   +8 more
semanticscholar   +1 more source